Cenix to Conduct RNAi-Based Target Discovery for Boehringer Ingelheim
The Cellenger image-analysis platform will be used to develop assays.!--h2>
Cenix BioScience will help Boehringer Ingelheim discover novel therapeutic drug targets. The firm will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in what will be a genome-scale screen using cultured human cells.
Multiparametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be used to complement Boehringer Ingelheim’s assays to generate insights into the cellular functions and loss-of-function phenotypes of analyzed genes.
Such RNAi datasets offer a highly predictive and cost-effective basis for mining the human genome to discover and prioritize targets for therapeutic drug development in a wide range of disease fields, according to Cenix.